POLYMER THERAPEUTICS for Drug Delivery
.
circle-arrow-right Polymers as
Door Openers
Discover our polymer products suitable for drug delivery including poly(ethyleneglycol) s (PEGs), poly(amino acid)s (PArg, PGlu, PLys, POR, PSar), poly(oxazoline)s, as well as lipidated polymers and co-polymers. pages 1-3
Poly(ethylene glycol)s -
Innovative (co)polymers based
Benefit of our services -
oldies but goldies.
on poly(amino acid)s and po-
let us be your partner!
page 1
ly(oxazoline)s. page 2,3
page 4 Version: IF20_2
Polymer Therapeutics
Polymer Therapeutics for Drug Delivery Poly(ethylene glycol)s Small drug molecules like peptides and other biomolecules have high potential as drugs due to their specificity and efficacy in combination with low side effects. However, they suffer from rapid clearance from the human body and show poor pharmacokinetic properties which limits their applications. Due to the fact that such biomolecules are similar to biological components, they are easily attacked by the immune system of the body, i.e. by antibodies and degradation enzymes. Another limitation might be insufficient solubility. Thus, many promising novel drug molecules will never reach market approval. Attaching polymers which are tolerated by the physiologic systems, such as poly(amino acids), poly(ethylene glycol)s or other variants improves drastically their bioavailability and biodistribution and turns sensitive biomolecules into robust drugs. First attempts with polymers were made already in the 1960s – either by attaching the therapeutic agent covalently to a polymer or by entrapping it non-covalently in a polymer nanoparticle. Over the years, polymers have garnered attention in the evolution of drug delivery technologies for both water-soluble and hydrophobic drug molecules.
Pharmacokinetic properties of a PEGylated drug in comparison with a non-PEGylated drug.
The first polymer-drug conjugates that showed promising results contained poly(ethyleneglycol) (PEG). The pharmacological effects of PEG and many other first generation polymer attachments are mainly of physical nature. They act solubilizing due to their hydrophilicity, prevent degradation, and reduce immunogenicity by shielding the pharmaceutical and prevent excretion by increasing the hydrodynamic radius. Iris Biotech offers a portfolio of a thousand different PEG chemicals with a length ranging from only two ethylenglycol units (with a molecular weight around 100 g/mol) up to long chain PEGs of molecular weights beyond 20,000 g/mol. Further to this standard portfolio, we can produce for you also customized PEG variants according to your personal needs.
1
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
Poly(amino acid)s Eventhough PEGs still represent the most frequently used polymer for drug delivery, several possible side effects and complications are reported for this type of polymer, e.g. non-biodegradability/accumulation and immunogenicity. Besides, growing knowledge on drug delivery technologies allows to create “intelligent” systems which can help transporting a payload to a target destination or even to destinations where it could not go without the polymer’s help. Biodegradable poly(amino acid)s appear very attractive in this context. However, their availability in sufficient quality and quantity for broad pharmaceutical application was a bottleneck in the first years. At Iris Biotech, we are presenting biodegradable and biocompatible poly(amino acid)s (PArg, PGlu, PLys, POr, PSar) as well as poly(oxyzolines) as polymers for drug delivery.
General chemical structures of poly(amino acid)s and POx available at Iris Biotech.
Poly(sarcosines) have been employed in a number of drug delivery systems and are gaining increasing attention. Iris Biotech offers monofunctional, homo- and heterobifunctional poly(sarcosines) with a wide variety of functional groups. Degrees of polymerization (n) may range from below 10 to above 1,000. Thus, molar masses of approx. 1 kg/mol to 100 kg/mol are feasible. The use of poly(sarcosines) with functional head- and tail-groups for bioconjugation is comparable to the well-known PEGylation technology. In a study, a poly(sarcosine)- and PEG-conjugated Uricase were compared, and it was shown that the PSar conjugation is efficient in extending Uricase half-life in vivo more than 20-fold. Furthermore, PSar-Uricase is less immunogenic compared to either native or PEGylated Uricase in vivo, and polysarcosination did not affect the enzymatic activity.
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
2
Polymer Therapeutics Polymer-Lipid Conjugates
Case Study Uricase: PEGylation vs. Polysarcosination.
Almost all polymers discussed by now are water soluble – for good reason: most drug delivery systems are designed to transport their payload in the bloodstream and thus they must be highly water soluble. However, once the delivery complex has reached its destination, the picture turns to the opposite: if a cargo should enter a cell through the cell membrane (which mainly consists of a hydrophobic lipid bilayer), a highly hydrophilic transport system is rather counterproductive. Here, a lipophilic moiety should rather be helpful. Therefore, many drug delivery systems also contain hydrophobic blocks that help to form barrier-overbearing nanostructures such as micelles, liposomes, or lipid nanoparticles (LNPs). Especially in the curse of the worldwide Corona pandemic, the development of mRNA vaccines emphasized the importance of tools for secured RNA delivery as they themselves are unable to cross physiological barriers and are susceptible to enzymatic degradation by endogenous nucleases. Thus, for successful RNA drug delivery, polymer-conjugated lipid nanoparticles (LNPs) capable to permeate plasma membranes are reported in literature.
PGA Lipid combinations available at Iris Biotech. For more information, see related products.
3
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
PSar Lipid combinations available at Iris Biotech. For more information, see related products.
Copolymers Another attractive feature of the polymers presented is the fact that they can be combined with each other to form different types of copolymers, e.g. grafted polymers, random copolymers or block copolymers. This allows us to modify parameters such as size, conformation, charge, solubility, geometry, and topoplogy and opens a toolbox to an almost unlimited number of combinations specifically tailored to your particular needs.
Services Benefit of our services! Formulation of multiple bench-scale samples from 1-5 ml and scaling up from 0,2-5 l are available. Formulation services are mainly focused on the support of client-based screening assays and scale up. These services include optimization of key process parameters such as molar ratios, mixing flow rates, concentration, and flow speed. Our scientists support the development of polymer therapeutic substances and their analysis through the entire project life cycle from first R&D batches through pre-clinical material to final GMP- & GLPcertified commercial production and testing. Equipment and skills are specially suited but not limited to method development, validation, and stability studies.
Poly-Arginines Product details
PAR1060
nBu-PArg(20)*HCl
n-Butyl-poly-L-Arginine hydrochloride CAS-No. Mol. weight
O
26982-20-7 3800 Da
N H
(S)
H 20
HCl
HN HN
H N
NH2
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
4
Polymer Therapeutics Product details
PAR1020
nBu-PArg(50)*HCl
n-Butyl-poly-L-Arginine hydrochloride CAS-No. Mol. weight
O
26982-20-7 9600 Da
(S)
N H
HCl
HN NH2
nBu-PArg(100)*HCl
n-Butyl-poly-L-Arginine hydrochloride CAS-No. Mol. weight
O
26982-20-7 19000 Da
(S)
N H
H
HCl NH2
nBu-PArg(200)*HCl
n-Butyl-poly-L-Arginine hydrochloride CAS-No. Mol. weight
H N
100
HN HN
PAR1050
H 50
HN
PAR1030
H N
O
26982-20-7 38500 Da
(S)
N H
H 200
HCl
HN HN
H N
NH2
Poly-Glutamic Acids Product details
PGA1005
nBu-PGA(20)
n-Butyl-poly(L-glutamic acid) sodium salt CAS-No. Mol. weight
26247-79-0 3000 Da
O (S)
N H
H N
O- Na+
O
PGA1010
nBu-PGA(50)
n-Butyl-poly(L-glutamic acid) sodium salt CAS-No. Mol. weight
26247-79-0 7500 Da
O N H
(S)
H N
H 50
O
5
H 20
O- Na+
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
Product details
PGA1015
nBu-PGA(100)
n-Butyl-poly(L-glutamic acid) sodium salt CAS-No. Mol. weight
O
26247-79-0 15100 Da
H N
(S)
N H
H 100
O- Na+
O
PGA1020
nBu-PGA(200)
n-Butyl-poly(L-glutamic acid) sodium salt CAS-No. Mol. weight
O
26247-79-0 30200 Da
H N
(S)
N H
H 200
O- Na+
O
PGA1085
Prg-PGA(20)
Propargyl-poly(L-glutamic acid) sodium salt Mol. weight
3000 Da
O (S)
N H
H N
O- Na+
O
PGA1090
Prg-PGA(50)
Propargyl-poly(L-glutamic acid) sodium salt Mol. weight
7500 Da
O (S)
N H
H N
O- Na+
Prg-PGA(100)
Propargyl-poly(L-glutamic acid) sodium salt Mol. weight
15000 Da
O (S)
N H
H N
O- Na+
Prg-PGA(200)
Propargyl-poly(L-glutamic acid) sodium salt Mol. weight
H 100
O
PGA1100
H 50
O
PGA1095
H 20
30200 Da
O N H
(S)
H N
H 200
O
O- Na+
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
6
Polymer Therapeutics Product details
PGA1125
N3 -PGA(20)
Azido-ethyltri(ethylene glycol)-poly(L-glutamic acid) sodium salt Mol. weight
3000 Da
O N3
O
(S)
N H
3
H N
O- Na+
O
PGA1130
N3 -PGA(50)
Azido-ethyltri(ethylene glycol)-poly(L-glutamic acid) sodium salt Mol. weight
7500 Da
O N3
O
(S)
N H
3
H N
O- Na+
N3 -PGA(100)
Azido-ethyltri(ethylene glycol)-poly(L-glutamic acid) sodium salt Mol. weight
15000 Da
O N3
O
(S)
N H
3
H N
O- Na+
N3 -PGA(200)
Azido-ethyltri(ethylene glycol)-poly(L-glutamic acid) sodium salt Mol. weight
30000 Da
O N3
O
(S)
N H
3
H N
O- Na+
nBu-PGA(20)[Prg(20)]
n-Butyl-poly(L-glutamic acid gamma-propargyl amide) sodium salt (10-20mol% propargyl substitution) Mol. weight
3000 Da
O (S)
N H
(S)
x
O
N H
H 20 - x
NH
7500 Da
O- Na+
O O N H
O
7
H N
nBu-PGA(50)[Prg(20)]
n-Butyl-poly(L-glutamic acid gamma-propargyl amide) sodium salt (10-20mol% propargyl substitution) Mol. weight
O- Na+
O
O
PGA1195
H 200
O
PGA1190
H 100
O
PGA1140
H 50
O
PGA1135
H 20
(S)
H N
(S)
x
O
N H
H 50 - x
NH
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
Product details
PGA1200
nBu-PGA(100)[Prg(20)]
n-Butyl-poly(L-glutamic acid gamma-propargyl amide) sodium salt (10-20mol% propargyl substitution) Mol. weight
15000 Da
O (S)
N H
30000 Da
100 - x
O- Na+
O O (S)
N H
H N
(S)
x
O
H
N H
200 - x
NH
nBu-PGA(20)[PEG2-N3(20)]
n-Butyl-poly(L-glutamic acid gamma-azido-ethyltri(ethylene glycol) amide) sodium salt (1020mol% azido substitution) Mol. weight
H
N H
NH
O
PGA1290
(S)
O
nBu-PGA(200)[Prg(20)]
n-Butyl-poly(L-glutamic acid gamma-propargyl amide) sodium salt (10-20mol% propargyl substitution) Mol. weight
H N x
O
PGA1205
O- Na+
O
3600 Da
O- Na+
O O (S)
N H
H N
(S)
x
O
H
N H
20 - x
NH
O
O 3
PGA1295
nBu-PGA(50)[PEG2-N3(20)]
n-Butyl-poly(L-glutamic acid gamma-azido-ethyltri(ethylene glycol) amide) sodium salt (1020mol% azido substitution) Mol. weight
9100 Da
O- Na+
O O (S)
N H
H N
(S)
x
O
H
N H
50 - x
NH
O
O 3
PGA1300
18300 Da
O- Na+
O O (S)
N H
H N
(S)
x
O
H
N H
100 - x
NH
O
O 3
PGA1305
N3
nBu-PGA(200)[PEG2-N3(20)]
n-Butyl-poly(L-glutamic acid gamma-azido-ethyltri(ethylene glycol) amide) sodium salt (1020mol% azido substitution) Mol. weight
N3
nBu-PGA(100)[PEG2-N3(20)]
n-Butyl-poly(L-glutamic acid gamma-azido-ethyltri(ethylene glycol) amide) sodium salt (1020mol% azido substitution) Mol. weight
N3
36700 Da
O- Na+
O O N H
O
(S)
H N
(S)
x
O
H
N H
200 - x
NH O 3
N3
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
8
Polymer Therapeutics Product details
PGA1490
nBu-PGA(20)[mPEG(20)]
n-Butyl-poly(L-glutamic acid gamma-(omega-methoxyhepta(ethylene glycol))) sodium salt (10-20mol% mPEG substitution) Mol. weight
O- Na+
O O (S)
N H
4300 Da
H N
(S)
x
O
H
N H
20 - x
NH
O
O 6
PGA1495
nBu-PGA(50)[mPEG(20)]
n-Butyl-poly(L-glutamic acid gamma-(omega-methoxyhepta(ethylene glycol))) sodium salt (10-20mol% mPEG substitution) Mol. weight
O- Na+
O O (S)
N H
10900 Da
H N
(S)
x
O
H
N H
50 - x
NH
O
O 6
PGA1500
O- Na+
O O (S)
N H
21800 Da
H N
(S)
x
O
H
N H
100 - x
NH
O
O 6
PGA1505
O- Na+
O O N H
40600 Da
O
(S)
H N
(S)
x
O
H
N H
200 - x
NH O 6
PGA1700
OMe
Aldehyde-PGA(20)tBu
(4,4-Diethoxybutyl)-poly(sodium L-glutamato) pivalate Mol. weight
OMe
nBu-PGA(200)[mPEG(20)]
n-Butyl-poly(L-glutamic acid gamma-(omega-methoxyhepta(ethylene glycol))) sodium salt (10-20mol% mPEG substitution) Mol. weight
OMe
nBu-PGA(100)[mPEG(20)]
n-Butyl-poly(L-glutamic acid gamma-(omega-methoxyhepta(ethylene glycol))) sodium salt (10-20mol% mPEG substitution) Mol. weight
OMe
3000 Da
O O O
(S)
N H
H N 20
O- Na+
O
PGA1710
Aldehyde-PGA(50)tBu
(4,4-Diethoxybutyl)-poly(sodium L-glutamato) pivalate Mol. weight
7600 Da
O O O
N H
(S)
H N 50
O
9
O
O O- Na+
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
Product details
PGA1720
Aldehyde-PGA(100)tBu
(4,4-Diethoxybutyl)-poly(sodium L-glutamato) pivalate Mol. weight
15100 Da
O O O
H N
(S)
N H
100
O- Na+
O
PGA1740
Aldehyde-PGA(200)tBu
(4,4-Diethoxybutyl)-poly(sodium L-glutamato) pivalate Mol. weight
30200 Da
O O
H N
(S)
N H
O
200
nBu-PGA(20)[Hyd(20)]
n-Butyl-poly(L-glutamic acid gamma-t-butyl carbazate) sodium salt (10-20mol% substitution) Mol. weight
O O- Na+
O
PGA1810
O
O (S)
N H
3700 Da
O- Na+
O
H N
(S)
x
O
N H
H 20 - x
NH
O
HN
O O
PGA1770
nBu-PGA(100)[Hyd(20)]
n-Butyl-poly(L-glutamic acid gamma-t-butyl carbazate) sodium salt (10-20 mol% substitution, MW 20200Da) Mol. weight
O (S)
N H
20200 Da
O- Na+
O
H N
(S)
x
O
N H
H 100 - x
NH
O
HN
O O
PGA1830
nBu-PGA(200)[Hyd(20)]
n-Butyl-poly(L-glutamic acid gamma-t-butyl carbazate) sodium salt (10-20mol% substitution) Mol. weight
O (S)
N H
40100 Da
O- Na+
O
H N
(S)
x
O
N H
H 200 - x
NH
O
HN
O O
PGA1870
nBu-PGA(50)[Hyd(20)]
n-Butyl-poly(L-glutamic acid gamma-t-butyl carbazate) sodium salt (10-20mol% substitution) Mol. weight
9900 Da
O- Na+
O O N H
O
(S)
H N
(S)
x
O
N H
H 50 - x
NH HN
O O
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
10
Polymer Therapeutics Product details
PGA1880
C14-[PGA(DIOL)]10 -H
(Tetradecylamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide)acetamide Mol. weight
O
H N
(S)
N H
H 10
2000 Da
O
NH
HO
HO
PGA1890
C14-[PGA(DIOL)]20 -H
(Tetradecylamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide)acetamide Mol. weight
O
H N
(S)
N H
H 20
4000 Da
O
NH
HO
HO
PGA1900
C14-[PGA(DIOL)]10 -COCH3
(Tetradecylamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide)acetamide Mol. weight
O
H N
(S)
N H
10 O
2000 Da O
NH
HO
HO
PGA1910
C14-[PGA(DIOL)]20 -COCH3
(Tetradecylamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide)acetamide Mol. weight
O N H
4000 Da
H N
(S)
20
O
O
NH
HO
HO
PGA1920
DMPE-[PGA(DIOL)]30 -H
(1,2-Dimyristoyl-glycero-3-phosphoethanolamine)-poly-L-glutamic acid(gamma-dihydroxypropylamide) acetamide Mol. weight
7000 Da
O O O O
(R)
O
OH P O
O O
N H
(S)
H 30
O HO
HO
11
H N
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
NH
Poly-Lysines Product details
PLY1030
nBu-PLys(20)*HCl
n-Butyl-poly-L-Lysine hydrochloride CAS-No. Mol. weight
O
26124-78-7 3300 Da
(S)
N H
H N
H 20
HCl NH2
PLY1031
nBu-PLys(20)*HBr
n-Butyl-poly-L-Lysine hydrobromide CAS-No. Mol. weight
O
26124-78-7 4200 Da
(S)
N H
H N
H 20
HBr NH2
PLY1001
nBu-PLys(50)*HBr
n-Butyl-poly-L-Lysine hydrobromide CAS-No. Mol. weight
O
26124-78-7 10500 Da
(S)
N H
H N
H 50
HBr NH2
PLY1010
nBu-PLys(100)*HCl
n-Butyl-poly-L-Lysine hydrochloride CAS-No. Mol. weight
O
26124-78-7 16000 Da
(S)
N H
H N
H 100
HCl NH2
PLY1011
nBu-PLys(100)*HBr
n-Butyl-poly-L-Lysine hydrobromide CAS-No. Mol. weight
O
26124-78-7 20900 Da
N H
(S)
H N
H 100
HBr NH2
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
12
Polymer Therapeutics Product details
PLY1020
nBu-PLys(200)*HCl
n-Butyl-poly-L-Lysine hydrochloride CAS-No. Mol. weight
O
26124-78-7 32500 Da
H N
(S)
N H
H 200
HCl NH2
PLY1021
nBu-PLys(200)*HBr
n-Butyl-poly-L-Lysine hydrobromide CAS-No. Mol. weight
O
26124-78-7 42000 Da
(S)
N H
H N
H 200
HBr NH2
Poly-Ornithines Product details
POR1060
nBu-POR(20)*HCl
n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight
O
26982-21-8 3000 Da HCl
POR1020
O
26982-21-8 5800 Da
H N
H 50
H2N
nBu-POR(100)*HCl O
26982-21-8 15000 Da
N H
HCl
13
(S)
N H
n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight
H 20
nBu-POR(50)*HCl
HCl
POR1030
H N
H2N
n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight
(S)
N H
(S)
H N
H 100
H2N
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
Product details
POR1040
nBu-POR(150)*HCl
n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight
O
26982-21-8 22600 Da HCl
POR1050
H N
H 150
H2N
nBu-POR(200)*HCl
n-Butyl-poly-L-Ornithine hydrochloride CAS-No. Mol. weight
(S)
N H
O
26982-21-8 30100 Da
(S)
N H
HCl
H N
H 200
H2N
Poly-Sarcosines Product details
PSR1740
Mal-PSar-OMe (5 kDa)
N-alpha-(3-maleimido)-propanamide polysarcosine omega-methoxyethylamide
O O
N
N
OMe
nH
O
PSR1750
N
O
Mal-PSar-OMe (10 kDa)
N-alpha-(3-maleimido)-propanamide polysarcosine omega-methoxyethylamide
O O
N
N
OMe
nH
O
PSR1760
N
O
Mal-PSar-OMe (15 kDa)
N-alpha-(3-maleimido)-propanamide polysarcosine omega-methoxyethylamide
O O
N
N
OMe
nH
O
N
O
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
14
Polymer Therapeutics Product details
PSR1770
NHS-PSar-OMe (5 kDa)
N-alpha-(succinimidylester)-polysarcosine omega-methoxyethylamide
O O
N
N
N
OMe
nH
O
O
O
O
PSR1780
NHS-PSar-OMe (10 kDa)
N-alpha-(succinimidylester)-polysarcosine omega-methoxyethylamide
O O
N
N
N
OMe
nH
O
O
O
O
PSR1790
NHS-PSar-OMe (15 kDa)
N-alpha-(succinimidylester)-polysarcosine omega-methoxyethylamide
O O
N
N
N
OMe
nH
O
O
O
O
PSR1830
VitE-PSar10
N-alpha-isopropyl polysarcosine(10) N-omega-(Vitamine E)-4-oxobutanoate Mol. weight
O N
N H
O 10
1300 Da
O
O
O
PSR1820
VitE-PSar20
N-alpha-isopropyl polysarcosine(20) N-omega-(Vitamine E)-4-oxobutanoate Mol. weight
2000 Da
O N H
N
O 20
O
O
O
15
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
Poly-Oxazolines Product details
POX1200
Me-PMeOx(50)-N3
alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight
Me
26375-28-0 CH3 (C 4H7NO)50N3 4300 Da
O
POX1210
Me
26375-28-0 CH3 (C 4H7NO)100N3 8500 Da
Me
100 Me
Me-PEtOx(50)-N3
alpha-Methyl-poly(2-ethyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight
25805-17-8 CH3 (C 5H9NO)50N3 5000 Da
POX2210
Me-PEtOx(100)-N3
Me
CAS-No. Formula Mol. weight
25805-17-8 CH3 (C 5H9NO)100N3 5000 Da
POX1220
Me-PMeOx(50)-NH2*HCl
alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-amine hydrochloride 26375-28-0 CH3 (C 4H7NO)50NH2*HCl 4300 Da
N
N3 50
O
alpha-Methyl-poly(2-ethyl-2-oxazoline)-omega-azide
CAS-No. Formula Mol. weight
N3
N
O
POX2200
50
Me-PMeOx(100)-N3
alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight
N3
N
Me
N
N3 100
O
Me
O
NH3+Cl-
N
50 Me
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
16
Polymer Therapeutics Product details
POX1230
Me-PMeOx(100)-NH2*HCl
alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-amine hydrochloride CAS-No. Formula Mol. weight
26375-28-0 CH3 (C 4H7NO)100NH2*HCl 8500 Da
POX2220
Me-PEtOx(50)-NH2*HCl
Me
O
alpha-Methyl-poly(2-ethyl-2-oxazoline)-omega-amine hydrochloride CAS-No. Formula Mol. weight
25805-17-8 CH3 (C 5H9NO)50NH2*HCl 5000 Da
POX2230
Me-PEtOx(100)-NH2*HCl 25805-17-8 CH3 (C 5H9NO)100NH2*HCl 10000 Da
POX1240
Me-PMeOx(50)-COOH
alpha-Methyl-poly(2-methyl-2-oxazoline)-omega-succinamic acid CAS-No. Formula Mol. weight
26375-28-0 CH3 (C 4H7NO)50COCH2CH2COOH 4300 Da
POX1241
HOOC-PMeOx(50)-Pip
alpha-Carboxymethyl-poly(2-methyl-2-oxazoline)-omega-Piperidine Formula Mol. weight
HOOCCH2 (C 4H7NO)50NC 6H12 4300 Da
POX2241
HOOC-PEtOx(50)-Pip
alpha-Carboxymethyl-poly(2-ethyl-2-oxazoline)-omega-piperidine Formula Mol. weight
17
HOOC-CH2 (C 5H9NO)50NC 6H12 5000 Da
100 Me
Me
NH3+Cl-
N
50
O
alpha-Methyl-poly(2-ethyl-2-oxazoline)-omega-amine hydrochloride CAS-No. Formula Mol. weight
NH3+Cl-
N
Me
NH3+Cl-
N
100
O
Me
N
O
O
H N 50 Me
HO
OH O
N
N O
O
HO
N O
50 Me
N 50
O
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
Product details
POX1250
HOOC-PMeOx(50)-N3
alpha-Carboxymethyl-poly(2-methyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight
26375-28-0 HOCOCH2 (C 4H7NO)50N3 4300 Da
POX2250
HOOC-PEtOx(50)-N3
alpha-Carboxymethyl-poly(2-ethyl-2-oxazoline)-omega-azide CAS-No. Formula Mol. weight
25805-17-8 HOCOCH2 (C 5H9NO)50N3 5000 Da
HO
N3
N O
O
HO
Me
N O
50
N3 50
O
References: → Rational design of polyarginine nanocapsules intended to help peptides overcoming intestinal barriers; Z. Niu, E. Tedesco, F. Benetti, A. Mabondzo, I. M. Montagner, I. Marigo, D. Gonzalez-Touceda, S. Tovar, C. Diéguez, M. J. Santander-Ortega, M. J. Alonso; Journal of Controlled Release 2017; 263: 4-17. https://doi.org/10.1016/j.jconrel.2017.02.024 → Polyarginine nanocapsules: a new platform for intracellular drug delivery; M. V. Lozano, G. Lollo, M. Alonso-Nocelo, J. Brea, A. Vidal, D. Torres, M. J. Alonso; Journal of Nanoparticle Research 2013; 15: 1515. https://doi.org/10.1007/s11051-013-1515-7 → Suppressive immune response of poly-(sarcosine) chains in peptide-nanosheets in contrast to polymeric micelles; E. Hara, M. Ueda, C. J. Kim, A. Makino, I. Hara, E. Ozeki, S. Kimura; J. Pept. Sci. 2014; 20: 570-577. https://doi.org/10.1002/psc.2655 → Thermoresponsive release from poly(Glu(OMe))-block-poly(Sar) microcapsules with surface-grafting of poly(N-isopropylacrylamide); T. Kidchob, S. Kimura, Y. Imanishi; J. Control. Release 1998; 50: 205-14. https://doi.org/10.1016/s0168-3659(97)00135-1 → Amphiphilic poly(Ala)-b-poly(Sar) microspheres loaded with hydrophobic drug; T. Kidchob, S. Kimura, Y. Imanishi; J. Control. Release 1998; 51: 241-248. https://doi.org/10.1016/s0168-3659(97)00176-4 → On the biodegradability of polyethylene glycol, polypeptoids and poly(2-oxazoline)s; J. Ulbricht, R. Jordan, R. Luxenhofer; Biomaterials 2014; 35: 4848-4861. https://doi.org/10.1016/j.biomaterials.2014.02.029 → Polysarcosine as an Alternative to PEG for Therapeutic Protein Conjugation; Y. Hu, Y. Hou, H. Wang, H. Lu; Bioconjugate Chem. 2018; 29(7): 2232-2238. https://doi.org/10.1021/acs.bioconjchem.8b00237 → Polysarcosine-containing copolymers: Synthesis, characterization, self-assembly, and applications; A. Birke, J. Ling, M. Barz; Prog. Polym. Sci. 2018; 81: 163-208. https://doi.org/10.1016/j.progpolymsci.2018.01.002 → Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery; S. S. Nogueira, A. Schlegel, K. Maxeiner, B. Weber, M. Barz, M. A. Schroer, C. E. Blanchet, D. I. Svergun, S. Ramishetti, D. Peer, P. Langguth, U. Sahin, H. Haas; ACS Appl. Nano Mater. 2020; 3(11): 10634-10645. https://doi.org/10.1021/acsanm.0c01834 → Polyamide/Poly(Amino Acid) Polymers for Drug Delivery; S. H. S. Boddu, P. Bhagav, P. K. Karla, S. Jacob, M. D. Adatiya, T. M. Dhameliya, K. M. Ranch, A. K. Tiwari; J. Funct. Biomater. 2021; 12(4): 58. https://doi.org/10.3390/jfb12040058
Iris Biotech GmbH • Email: info@iris-biotech.de • www.iris-biotech.de • Empowering Peptide Innovation
18
Empowering Peptide Innovation